Belpointe Asset Management LLC Makes New $767,000 Investment in HCA Healthcare, Inc. $HCA

Key Points

• Belpointe Asset Management LLC has made a new investment of approximately $767,000 in HCA Healthcare, acquiring 2,221 shares during the first quarter.
• HCA Healthcare recently announced a quarterly dividend of $0.72 per share, which will be paid to shareholders on September 30th, providing an annualized yield of 0.7%.
• The stock price of HCA Healthcare has increased by 0.7% and opened at $405.54 on the market, following a stronger than expected earnings report.

Belpointe Asset Management LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,221 shares of the company's stock, valued at approximately $767,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Cheviot Value Management LLC bought a new position in HCA Healthcare during the 1st quarter worth approximately $26,000. Saudi Central Bank acquired a new stake in shares of HCA Healthcare during the 1st quarter worth approximately $26,000. WPG Advisers LLC acquired a new stake in shares of HCA Healthcare during the 1st quarter worth approximately $27,000. Atwood & Palmer Inc. acquired a new stake in shares of HCA Healthcare during the 1st quarter worth approximately $28,000. Finally, Bartlett & CO. Wealth Management LLC grew its position in shares of HCA Healthcare by 888.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company's stock worth $31,000 after buying an additional 80 shares during the period. Institutional investors own 62.73% of the company's stock.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the business's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares of the company's stock, valued at approximately $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

HCA Healthcare Stock Up 0.7%

HCA stock opened at $405.54 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. The firm has a market capitalization of $94.89 billion, a PE ratio of 17.05, a PEG ratio of 1.27 and a beta of 1.41. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $420.98. The stock has a 50-day simple moving average of $382.88 and a two-hundred day simple moving average of $362.77.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. The business had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The company's quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 16th. HCA Healthcare's payout ratio is presently 12.11%.

Analyst Ratings Changes

HCA has been the subject of several recent analyst reports. Bank of America raised their price objective on shares of HCA Healthcare from $375.00 to $410.00 and gave the stock a "neutral" rating in a research report on Wednesday. Wolfe Research downgraded shares of HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research report on Monday, July 28th. Wall Street Zen raised shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. JPMorgan Chase & Co. lifted their price target on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a "neutral" rating in a research report on Monday, August 4th. Finally, Morgan Stanley reduced their price target on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, HCA Healthcare presently has an average rating of "Moderate Buy" and an average target price of $403.17.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.